Vactosertib, a novel TGF-β1 type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed/refractory multiple myeloma

Functional blockade of the transforming growth factor-beta (TGF-β) signaling pathway improves the efficacy of cytotoxic and immunotherapies. We conducted a phase 1b study to determine the safety, efficacy, and maximal tolerated dose (200 mg po bid) of the potent, orally-available TGF-β type I recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Ehsan, Rana, Priyanka S., Swamydas, Muthulekha, Daunov, Michael, Miyagi, Masaru, Murphy, Elena, Ignatz-Hoover, James J., Metheny, Leland, Seong Jin, Kim, Driscoll, James J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371138/
https://www.ncbi.nlm.nih.gov/pubmed/37503043
http://dx.doi.org/10.21203/rs.3.rs-3112163/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371138/
https://www.ncbi.nlm.nih.gov/pubmed/37503043
http://dx.doi.org/10.21203/rs.3.rs-3112163/v1

Ejemplares similares